New radiation method aims to protect scalp in brain tumor patients
NCT ID NCT03251027
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a precise type of radiation therapy (IM-SRT) for people with newly diagnosed grade II to IV gliomas. The goal is to deliver a high dose of radiation directly to the tumor while minimizing damage to the scalp, which may reduce wound infections and the need for metal implants after surgery. About 100 participants will receive this treatment and be monitored for complications and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Intensity-modulated stereotactic radiotherapy (IM-SRT)
What this could lead to
If successful, this approach could reduce wound infections and the need for titanium implants after brain tumor surgery, improving recovery and quality of life.
What could go wrong
This is a single-arm phase II trial with 100 participants, so results may not apply to all patients. The technique may not control the tumor as well as standard radiation, and scalp-sparing benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States